John S. Penta

1.4k total citations
26 papers, 1.1k citations indexed

About

John S. Penta is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, John S. Penta has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in John S. Penta's work include Cancer therapeutics and mechanisms (4 papers), Mitochondrial Function and Pathology (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). John S. Penta is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Mitochondrial Function and Pathology (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). John S. Penta collaborates with scholars based in United States, Malaysia and Italy. John S. Penta's co-authors include William C. Copeland, F. M. Johnson, J. T. Wachsman, Daniel D. Von Hoff, Salvador Bruno, Lee J. Helman, M Slavík, Franco M. Muggia, Raymond B. Weiss and Marcel Rozencweig and has published in prestigious journals such as Cancer Treatment Reviews, Mutation Research/Reviews in Mutation Research and Cancer Chemotherapy and Pharmacology.

In The Last Decade

John S. Penta

26 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John S. Penta United States	15	605	227	161	137	103	26	1.1k
Wai‐Nang Paul Lee United States	19	831 1.4×	511 2.3×	129 0.8×	64 0.5×	78 0.8×	28	1.4k
Ronald W. Trewyn United States	17	1.1k 1.9×	187 0.8×	136 0.8×	51 0.4×	35 0.3×	37	1.4k
Pirjo Koistinen Finland	19	619 1.0×	129 0.6×	204 1.3×	125 0.9×	54 0.5×	52	1.2k
M.G. Donelli Italy	19	305 0.5×	133 0.6×	474 2.9×	148 1.1×	25 0.2×	60	1.1k
Christelle Cauffiez France	23	720 1.2×	351 1.5×	239 1.5×	148 1.1×	63 0.6×	60	1.5k
Hidenori Kawashima Japan	23	426 0.7×	127 0.6×	257 1.6×	159 1.2×	32 0.3×	59	1.1k
Sandhya Xavier United States	20	567 0.9×	126 0.6×	123 0.8×	131 1.0×	89 0.9×	28	1.5k
Carole L. Banka United States	20	478 0.8×	172 0.8×	121 0.8×	70 0.5×	91 0.9×	31	1.6k
Jiekai Yu China	21	789 1.3×	240 1.1×	255 1.6×	163 1.2×	25 0.2×	73	1.5k
J M Hoeg United States	26	653 1.1×	415 1.8×	120 0.7×	76 0.6×	56 0.5×	42	2.0k

Countries citing papers authored by John S. Penta

Since Specialization

Citations

This map shows the geographic impact of John S. Penta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Penta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Penta more than expected).

Fields of papers citing papers by John S. Penta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Penta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Penta. The network helps show where John S. Penta may publish in the future.

Co-authorship network of co-authors of John S. Penta

This figure shows the co-authorship network connecting the top 25 collaborators of John S. Penta. A scholar is included among the top collaborators of John S. Penta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John S. Penta. John S. Penta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Copeland, William C., J. T. Wachsman, F. M. Johnson, & John S. Penta. (2003). Mitochondrial DNA Alterations in Cancer. ChemInform. 34(1). 10 indexed citations

2.

Copeland, William C., J. T. Wachsman, F. M. Johnson, & John S. Penta. (2002). Mitochondrial DNA Alterations in Cancer. Cancer Investigation. 20(4). 557–569. 184 indexed citations

3.

Penta, John S., F. M. Johnson, J. T. Wachsman, & William C. Copeland. (2001). Mitochondrial DNA in human malignancy. Mutation Research/Reviews in Mutation Research. 488(2). 119–133. 376 indexed citations

4.

Penta, John S., Gary L. Rosner, & Donald L. Trump. (1992). Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemotherapy and Pharmacology. 31(3). 247–250. 25 indexed citations

5.

Adamson, Peter C., Frank M. Balis, J. Miser, et al.. (1992). Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.. PubMed. 52(3). 521–4. 27 indexed citations

6.

Penta, John S., et al.. (1982). PCNU. American Journal of Clinical Oncology. 5(1). 9–12. 3 indexed citations

7.

Bruno, Salvador, et al.. (1982). Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. American Journal of Clinical Oncology. 5(1). 53–60. 16 indexed citations

8.

Bruno, Salvador, et al.. (1982). Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. American Journal of Clinical Oncology. 5(1). 53–60. 1 indexed citations

9.

Penta, John S., et al.. (1981). Treatment of cancer chemotherapy-induced nausea and vomiting. 35 indexed citations

10.

Bruno, Salvador, et al.. (1981). Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland.. PubMed. 4(3). 301–7. 16 indexed citations

11.

Rozencweig, Marcel, Daniel D. Von Hoff, M. Staquet, et al.. (1981). Animal toxicology for early clinical trials with anticancer agents.. PubMed. 4(1). 21–8. 47 indexed citations

12.

Muggia, Franco M., Marcel Rozencweig, & John S. Penta. (1980). Clinical Implications of Cisplatin Pharmacology. Recent results in cancer research. 74. 132–138. 6 indexed citations

13.

Penta, John S., et al.. (1980). Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.. PubMed. 3(4). 315–20. 4 indexed citations

14.

Guarino, Anthony M., Marcel Rozencweig, I Kline, et al.. (1979). Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents.. PubMed. 39(6 Pt 1). 2204–10. 19 indexed citations

15.

Wasserman, Todd H., et al.. (1978). The hypoxic cell sensitizer programme in the United States.. PubMed. 3. 276–80. 13 indexed citations

16.

Hoff, Daniel D. Von, Marcel Rozencweig, Lee J. Helman, et al.. (1977). Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.. PubMed. 61(5). 759–68. 13 indexed citations

17.

Hoff, Daniel D. Von, John S. Penta, Lee J. Helman, & M Slavík. (1977). Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.. PubMed. 61(4). 745–8. 102 indexed citations

18.

Bellet, Robert E., Marcel Rozencweig, Daniel D. Von Hoff, et al.. (1977). ICRF-159: Current status and clinical prospects. European Journal of Cancer (1965). 13(11). 1293–1298. 16 indexed citations

19.

Davignon, J. Paul, et al.. (1976). Investigational Drug Information. Drug Intelligence & Clinical Pharmacy. 10(1). 48–49. 1 indexed citations

20.

Hrushesky, William J.M., Milan Slavik, John S. Penta, & Franco M. Muggia. (1976). The “other” asparaginase. Medical and Pediatric Oncology. 2(4). 441–442. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact